Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients with diabetes mellitus (DM) type 2 have a high prevalence of coronary artery disease (CAD), as diabetes is implicated in the formation of atherosclerotic plaque. Hyperglycemia, elevated free fatty acid, increased amount of circulating end-glucosylated serum products and insulin resistance are the main mechanisms involved in the accelerated atherosclerotic process observed in type 2 DM patients. Novel treatments have been proposed to prevent and treat CAD in patients with diabetes, mainly in those with diabetes type 2. Several clinical trials have been designed in order to examine the effectiveness of these agents, such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, glitazones, statins and antioxidants, but the results are still controversial.

Type

Journal article

Journal

Curr Pharm Des

Publication Date

2009

Volume

15

Pages

2037 - 2048

Keywords

Clinical Trials as Topic, Coronary Artery Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Treatment Outcome